Vitamin K1 (Phytonadione).

UBIAD1 converts phylloquinone into menaquinone-4 in tissues, so K1 is a direct upstream source of a K2 form. Both then serve the same gamma-carboxylase.

K1 is cleared quickly and taken up largely by the liver, while MK-7 circulates for days and reaches bone and vessel wall. Together they cover hepatic clotting factor carboxylation and the extrahepatic Gla proteins.

Vitamin D drives production of osteocalcin and matrix Gla protein, and vitamin K carboxylates them so they can bind calcium. The steps run in sequence on one substrate.

Carboxylated Gla proteins are what let calcium be held in bone matrix rather than deposited in soft tissue. Vitamin K status therefore shapes where a calcium dose goes.

Phylloquinone is fat soluble and needs dietary lipid to form the micelles it is absorbed in. Taking it with fat raises uptake substantially over a dry dose alone.

High alpha-tocopherol intakes interfere with vitamin K recycling and lower carboxylation of clotting factors. A large vitamin E dose acts against K1 rather than alongside it.

Vitamin K1 supplies the carboxylated clotting factors while long-chain omega-3s damp platelet aggregation and thromboxane formation. The two push normal clotting in opposite directions, which a formula should account for rather than ignore.

Garlic organosulfur compounds reduce platelet aggregation, working against the clotting side that vitamin K supports. The interaction is directional rather than additive.

Ginkgolides antagonise platelet activating factor and reduce aggregation. That is the opposite direction to the clotting factor carboxylation vitamin K1 supplies.

Phytonadione is absorbed in the upper small intestine by an energy-dependent process that requires incorporation into mixed micelles, and micelle formation requires bile salts. Where bile flow is reduced, uptake of all fat-soluble vitamins falls. Supplemental bile acids are used in that setting on this mechanism.

Dietary triglyceride has to be hydrolysed by lipase before the resulting fatty acids and monoglycerides can form micelles with bile salts, and it is those micelles that carry phylloquinone across the brush border. Poor fat digestion therefore lowers vitamin K1 uptake independently of intake. This is standard fat-soluble vitamin absorption biochemistry.

Phytonadione is an oil-soluble quinone that disperses poorly in water, and phospholipid emulsifiers form the vesicles that keep it suspended in liquids, gummies and emulsions. That is why lecithin appears next to it on so many labels. The benefit is delivery and stability, not a change to what the vitamin does.

Absorbed phylloquinone is packaged into chylomicrons whose surface is built from phospholipid, and it circulates in triglyceride-rich lipoproteins. Phosphatidylcholine is also used as an emulsifier in the formulation itself. Both roles are physical carriage rather than an effect on carboxylation.

Taking phytonadione with an oil raises the amount absorbed, because the vitamin partitions into the lipid phase and travels with it into micelles. Krill oil supplies phospholipid-bound fatty acids that serve that role. The interaction is about the vehicle, and the same holds for any dietary fat.

Carotenoids and phylloquinone are both carried in mixed micelles and then in triglyceride-rich lipoproteins, and high single doses of one can reduce the fractional absorption of the other. The competition is dose dependent and matters far less at food-level intakes. Spacing large doses is the practical response.

Retinyl esters and phylloquinone both require micellar solubilisation and both leave the enterocyte in chylomicrons, so very large doses of one occupy capacity the other would use. High-dose vitamin A has long been described as reducing vitamin K availability on this basis. At ordinary multivitamin amounts the effect is small.

Lutein is a lipophilic xanthophyll absorbed by the same micelle-dependent route as vitamin K1, so a concentrated dose of either can crowd the other. Both also occur together naturally in leafy greens, where the amounts are modest. The competition is a high-dose supplement question, not a food one.

Tocotrienols share the absorption route and, like tocopherols, interact with vitamin K handling at high intakes. High-dose vitamin E has a documented effect on vitamin K status. Where both are dosed heavily, spacing or monitoring is the usual response.

Vitamin K1 supports the gamma-carboxylation of Gla proteins including osteocalcin and matrix Gla protein, while magnesium sits in the mineral phase and in parathyroid signalling. The two touch normal bone maintenance from different angles. There is no combination trial, so this is background physiology.

Boron influences calcium and magnesium handling and appears in bone-support formulas alongside vitamin K. The mechanisms are separate and neither has been tested against the other. The pairing is formulation logic with a mechanistic rationale.

Vitamin K1 is the cofactor that lets the liver carboxylate clotting factors II, VII, IX and X, while nattokinase is a fibrinolytic enzyme. Combining them puts two opposing influences on the same system, and anyone whose clotting is being managed needs that flagged. Natto itself is a rich source of menaquinone-7, so the source material and the isolated enzyme differ.

Bromelain reduces platelet aggregation, which pulls against the procoagulant side that vitamin K supports through factor carboxylation. The two are not usually taken for the same reason, so the overlap is worth flagging rather than pursuing. Anyone on clotting-related medication should raise both with their clinician.

Salicylate irreversibly inhibits platelet COX-1 and reduces thromboxane-driven aggregation, an effect on platelets rather than on the vitamin K dependent clotting factors. The two sit on opposite sides of haemostasis by different mechanisms. The flag is the combined picture, not a chemical interaction.

Curcumin reduces platelet aggregation in preclinical work, which works against the coagulation side vitamin K supports. Human data at supplement doses are limited and the effect size is not established. It belongs on the interaction list for anyone whose clotting is being managed.

Colonic bacteria including Bacteroides and Escherichia coli produce long-chain menaquinones, a vitamin K pool separate from dietary phylloquinone. How much of that bacterial K is absorbed from the colon is uncertain and probably small. Changing the flora changes that pool, which is a modulating relationship rather than a supplementation strategy.

Activated charcoal adsorbs fat-soluble compounds including vitamins, so taking it near a phytonadione dose lowers how much is absorbed. This is a general adsorption effect and applies to most oral actives. Separating doses by several hours is the standard handling.

A viscous gel-forming fibre raises the diffusion barrier between micelles and the brush border, which can lower fat-soluble vitamin uptake when both are taken together. The effect is modest at usual fibre intakes. Taking the vitamin apart from a fibre dose removes the question.

Regeneration of reduced vitamin K from its epoxide involves reductase activity with flavin- and NAD(P)H-dependent components, so flavin status sits in the background of the recycling loop. This is upstream cofactor biochemistry rather than a demonstrated supplement pairing. The dominant enzyme, VKORC1, is the rate-setting step.